Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC “capitulate”?

Lignende værker

• Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
  af: Seki, Nobuhiko, et al.
  Udgivet: (2019)
• RETRACTED: Clinical research on the efficacy of self-made sichongsan in combination with gefitinib on NSCLC patients with EGFR mutation
  af: Yibo Zhao, et al.
  Udgivet: (2018-06-01)
• Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study
  af: Seto, Takashi, et al.
  Udgivet: (2021)
• MET/HGF pathway activation as a paradigm of resistance to targeted therapies
  af: Ko, Brian, et al.
  Udgivet: (2017)
• Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
  af: Li, Yang-Ling, et al.
  Udgivet: (2018)